45 results on '"Astolfi, Monica"'
Search Results
2. Rituximab Induces Effective Clearance of Minimal Residual Disease in Molecular Relapses of Mantle Cell Lymphoma
3. Cells carrying nonlymphoma-associated bcl-2/IgH rearrangements (NLABR) are phenotypically related to follicular lymphoma and can establish as long-term persisting clonal populations
4. Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome
5. Telomere length correlates with histopathogenesis according to the germinal center in mature B-cell lymphoproliferative disorders
6. Long-Term Follow-Up of Indolent Lymphoma Patients Treated With High-Dose Sequential Chemotherapy and Autografting: Evidence That Durable Molecular and Clinical Remission Frequently Can Be Attained Only in Follicular Subtypes
7. PCR-Detectable Nonneoplastic Bcl-2/ IgH Rearrangements Are Common in Normal Subjects and Cancer Patients at Diagnosis but Rare in Subjects Treated With Chemotherapy
8. Recurrence of Bcl-2/IgH polymerase chain reaction positivity following a prolonged molecular remission can be unrelated to the original follicular lymphoma clone
9. High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO)
10. Real-time polymerase chain reaction in multiple myeloma: Quantitative analysis of tumor contamination of stem cell harvests
11. Clinical and molecular remission after allogeneic blood cell transplantation in a patient with mantle-cell lymphoma
12. A validated real-time quantitative PCR approach shows a correlation between tumor burden and successful ex vivo purging in follicular lymphoma patients
13. Heavy+Light Chain and Free Light Chain Assays at Baseline and During Follow-up in EMN02/HO95 Multiple Myeloma Clinical Trial
14. A Multicenter Phase I/II EMN Study of Carfilzomib in Combination with Bendamustine and Dexamethasone (CBd) in Relapsed and/or Refractory Patients with Multiple Myeloma
15. Extracellular Vesicles as Potential Biomarker for Acute Graft-Versus-Host-Disease
16. Hevylite and Freelite Tests in Newly Diagnosed Multiple Myeloma: Clinical Utility and Correlations with Clinical Features
17. Immunophenotypic profile and cytogenetic aberrations detected by interphase FISH in B-CLL patients
18. Impact of Complete Response on Survival with Either Autologous Stem Cell Transplantation or Conventional Chemotherapy: Results of a Pooled Analysis of 5 Phase III Trials in Newly Diagnosed Multiple Myeloma Patients
19. Multiple myeloma: New surface antigens for the characterization of plasma cells in the era of novel agents
20. 12p, 1p, 1q, 5q, 11q ABNORMALITIES AND IMMUNOPHENOTYPE IN MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE, MULTIPLE MYELOMA AND PLASMA CELL LEUKEMIA
21. Real-Time Polymerase Chain Reaction of Immunoglobulin Rearrangements for Quantitative Evaluation of Minimal Residual Disease in Myeloma
22. REAL TIME PCR IN MULTIPLE MYELOMA: QUANTITATIVE ANALYSIS OF TUMOR CONTAMINATION OF STEM CELL HARVESTS
23. MOLECULAR REMISSION IN A MULTIPLE MYELOMA PATIENT AFTER A NON MYELOABLATIVE ALLOGENEIC TRANSPLANT: PROOF OF PRINCIPLE
24. REAL TIME QUANTITATIVE PCR SHOWS THAT PERIPHERAK BLOOD STEM CELL (PBPC) HARVESTS ARE SIGNIFICANTILY LESS CONTAMINATED THAN BONE MARROW (BM) IN MULTIPLE MYELOMA PATIENTS (MM)
25. A Phase II Study With Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) For Newly Diagnosed Multiple Myeloma
26. Consolidation with Bortezomib, Thalidomide and Dexamethasone Induces Molecular Remissions in Autografted Multiple Myeloma Patients.
27. Multiple myeloma: New surface antigens for the characterization of plasma cells in the era of novel agents.
28. Immunoglobulin (Ig) Repertoire in Multiple Myeloma: High Frequency of Recurrent Aminoacid Substitutions in the FR2 and CDR2.
29. Impact of Early Consolidation with Bortezomib, Thalidomide and Dexamethasone on Molecularly-Detectable Disease in MM Patients in CR or VGPR Following Autologous Transplantation: Uncommon Achievement of Molecular Remission Despite Evidence of Tumor Load Reduction by Real Time PCR.
30. Array-Based Comparative Genomic Hybridization (Array-CGH) in Multiple Myeloma (MM) and Plasma Cell Leukemia (PCL): Recurrent Imbalances within a Highly Heterogeneous Background of Genomic Disruption.
31. Telomere Length Identifies Two Distinct Populations with Different Outcome among VH-Unmutated CLL Patients.
32. Telomerase Inhibitor BIBR1532 Induces Telomere Shortening and Growth Inhibition in Extra-Germinal Center (GC)-Derived Lymphoid Cell Lines.
33. Long-Term Monitoring of Cancer-Free Subjects Carrying Non-Lymphoma Associated bcl2/IgH Rearrangements (NLABR): Prolonged Persistence of Clonal Populations Potentially Related to Follicular Lymphoma (FL).
34. Cyclooxygenase-2 (COX-2) Is Frequently Expressed in Multiple Myeloma (MM) and Is Associated with Poor Outcome.
35. Sequential Brief Chemo-Immunotherapy FND + Rituximab in Elderly Patients with Advanced Stage Follicular Lymphoma (FL): High Clinical and Molecular Remission Rate Associated with a Prolonged Failure-Free Survival.
36. Long-Term Outcome of High-Dose Sequential Chemotherapy with Autografting (i-HDS) in Follicular Lymphoma at Diagnosis: An Update of the Prospective Multicenter Consecutive Trial of the "Gruppo Italiano Trapianto Di Midollo Osseo" (Gitmo).
37. PCR-Detectable Nonneoplastic Bcl-2/IgH Rearrangements Are Common in Normal Subjects and Cancer Patients at Diagnosis but Rare in Subjects Treated With Chemotherapy
38. Real-Time Polymerase Chain Reaction of Immunoglobulin Rearrangements for Quantitative Evaluation of Minimal Residual Disease in Myeloma.
39. Clinical relevance of minimal residual disease monitoring in mature B-cell disorders: role of qualitative and quantitative PCR-based strategies
40. Central Nervous System Relapse in a Patient with Mantle Cell Lymphoma in Continuous Clinical and Molecular Remission at Six Years Since Autografting
41. Molecular and Clinical Remissions in Multiple Myeloma: Role of Autologous and Allogeneic Transplantation of Hematopoietic Cells
42. Molecular Monitoring of Minimal Residual Disease in Follicular and Mantle Cell Non-Hodgkin's Lymphomas Treated With High-Dose Chemotherapy and Peripheral Blood Progenitor Cell Autografting
43. Multiple independent immunoglobulin class‐switch recombinations occurring within the same clone in myeloma
44. High-Dose Sequential Chemoradiotherapy in Multiple Myeloma: Residual Tumor Cells Are Detectable in Bone Marrow and Peripheral Blood Cell Harvests and After Autografting
45. Real-time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in myeloma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.